ArticleHaematologica2022

A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia.

Sumithira Vasu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.